Skip to main content
main-content

Osteoarthritis

Medications

Long-term impact unclear for knee OA medications

Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.

21-12-2018 | Osteoarthritis | Highlight | News

Long-term impact unclear for knee OA medications

Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.

Source:

JAMA 2018; 320: 2564–2579

19-12-2018 | Osteoarthritis | News

Targeting IL-1 ‘may not be effective’ for erosive hand OA

Findings from a randomized trial indicate that treatment with the interleukin-1α and -1β inhibitor lutikizumab does not improve pain or imaging outcomes among patients with erosive hand osteoarthritis.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213336

29-11-2018 | Osteoarthritis | Article

Intra-articular treatment options for knee osteoarthritis

Jones IA et al. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0123-4

18-10-2018 | Osteoarthritis | News

No pain relief with etanercept for hand OA

Treatment with the tumor necrosis factor inhibitor etanercept does not reduce pain at 24 weeks, compared with placebo, in patients with erosive hand osteoarthritis, preliminary trial data show.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213202

Calcium crystal deposition diseases: Beyond gout

In this review, the main clinical manifestations of calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition are discussed, along with the biological effects of these crystals, current therapeutic approaches and future directions in therapy [read more].
McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

19-09-2018 | Osteoarthritis | News

Extended-release triamcinolone acetonide viable for osteoarthritis patients with type 2 diabetes

Triamcinolone acetonide extended-release may be a good option for the treatment of knee osteoarthritis in patients with comorbid type 2 diabetes, suggest phase II study findings.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key265

18-09-2018 | Osteoarthritis | Review | Article

Fixed-dose combination amlodipine/celecoxib (Consensi) for hypertension and osteoarthritis

Smith SM, Cooper-DeHoff RM. Am J Med 2018. doi: 10.1016/j.amjmed.2018.08.027

06-09-2018 | Calcium crystal deposition disease | Review | Article

Calcium crystal deposition diseases: Beyond gout

McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

06-09-2018 | Osteoarthritis | Article

Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: A randomized, phase 2 study

Russell SJ et al. Rheumatology (Oxford) 2018: key265. doi: 10.1093/rheumatology/key265

Updated EULAR guidance for managing hand OA published

EULAR has issued updated recommendations for the management of hand osteoarthritis based on current evidence and expert opinion.

30-08-2018 | Osteoarthritis | Highlight | News

Updated EULAR guidance for managing hand OA published

EULAR has issued updated recommendations for the management of hand osteoarthritis based on current evidence and expert opinion.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213826

Oral OA therapy not linked to knee replacement risk

Exposure to oral osteoarthritis therapies is unlikely to be a risk factor for requiring knee replacement, suggests an analysis of the Osteoarthritis Initiative database.

28-08-2018 | Osteoarthritis | Article

2018 update of the EULAR recommendations for the management of hand osteoarthritis

Kloppenburg M et al. Ann Rheum Dis 2018. doi: 10.1136/annrheumdis-2018-213826

28-08-2018 | Osteoarthritis | Highlight | News

Oral OA therapy not linked to knee replacement risk

Exposure to oral osteoarthritis therapies is unlikely to be a risk factor for requiring knee replacement, suggests an analysis of the Osteoarthritis Initiative database.

Source:

Arthritis Res Ther 2018; 20: 172

17-08-2018 | Osteoarthritis | Article

Uptake of the NICE osteoarthritis guidelines in primary care: A survey of older adults with joint pain

Healey EL et al. BMC Musculoskelet Disord 2018; 19: 295. doi: 10.1186/s12891-018-2196-2

17-08-2018 | Osteoarthritis | Review | Article

Efficacy of commonly prescribed analgesics in the management of osteoarthritis: A systematic review and meta-analysis

Stewart M et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4132-z

23-07-2018 | Pain disorders | Review | Article

Current concepts and future directions of minimally invasive treatment for knee pain

Goldman DT et al. Curr Rheumatol Rep 2018; 20: 54. doi: 10.1007/s11926-018-0765-x

29-06-2018 | Osteoarthritis | News

DMARDs offer little pain relief for OA patients

Results of a systematic review and meta-analysis suggest that treatment with DMARDs does not offer clinically significant pain relief for patients with osteoarthritis.

Source:

Rheumatology 2018; Advance online publication

image credits